S. H. Advani

Specialty: Medicine

Location: Global

Tier: UNRANKED

H-Index: 0

Years Active: 0

Hospital Affiliations

• Hemato-oncology pioneer - Member

Key Publications

1. "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" - Blood (2016) [7633 citations]
2. "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma" - New England Journal of Medicine (2013) [1657 citations]
3. "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee" - Blood (2022) [1340 citations]
4. "Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies" - Journal of Clinical Oncology (2012) [1107 citations]
5. "Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma" - Nature Medicine (2015) [1096 citations]
6. "CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma" - New England Journal of Medicine (2018) [1071 citations]
7. "Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study" - Journal of Clinical Oncology (2012) [978 citations]
8. "Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia" - New England Journal of Medicine (2015) [913 citations]
9. "<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome" - Journal of Clinical Oncology (2016) [780 citations]
10. "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial" - The Lancet (2018) [704 citations]
11. "Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma" - New England Journal of Medicine (2013) [551 citations]
12. "Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines" - PLoS ONE (2012) [526 citations]
13. "Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy" - Blood (2016) [482 citations]
14. "In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study" - Journal of Clinical Oncology (2010) [481 citations]
15. "Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma" - Journal of Clinical Oncology (2018) [469 citations]

Knowledge Graph Relationships

S. H. Advani is a Medicine specialist affiliated with Hemato-oncology pioneer. Authored 50 scholarly articles.